Literature DB >> 7806144

Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease.

J George1, M Murray, K Byth, G C Farrell.   

Abstract

To determine whether cytochrome P450 proteins were differentially altered in severe chronic liver diseases, we examined 50 livers removed at liver transplantation from patients with end-stage cirrhosis, including 18 with and 32 without cholestasis, and compared the results with 21 histologically normal livers. NADPH-cytochrome c reductase activities were unaltered in microsomes from cirrhotic livers. Total cytochrome P450 content was significantly reduced. The catalytic activities of four xenobiotic-metabolizing P450s and the level of the corresponding proteins were differentially altered. Thus, P450 3A-supported testosterone 6 beta-hydroxylase activity and 3A protein appeared to be reduced, but only in the subgroup without cholestasis was this change significant. In contrast, 2E1 and the related N,N-dimethylnitrosamine N-demethylase activity were clearly reduced in livers from patients with cholestatic forms of cirrhosis but appeared not to be changed in other cirrhotic livers. Similarly, P450 2C protein was reduced only in patients with severe chronic cholestasis. Finally, P450 1A2 and 1A2-supported ethoxyresorufin O-deethylase activity were significantly reduced in hepatic microsomes from patients with both types of advanced liver disease. In summary, these data demonstrate that cytochrome P450 proteins are selectively altered in severe chronic liver disease, some being profoundly decreased, others less so or not at all. Our results also suggest that there may be different patterns of altered hepatic P450 expression according to the presence or absence of cholestasis in patients with cirrhosis severe enough to require transplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7806144

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  62 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 3.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 6.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

7.  Expression of P450 and nuclear receptors in normal and end-stage Chinese livers.

Authors:  Hong Chen; Zhong-Yang Shen; Wang Xu; Tie-Yan Fan; Jun Li; Yuan-Fu Lu; Ming-Liang Cheng; Jie Liu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 8.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.

Authors:  Anthony T Podany; Kimberly K Scarsi; Michelle M Pham; Courtney V Fletcher
Journal:  Clin Pharmacokinet       Date:  2020-09       Impact factor: 6.447

Review 9.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 10.  [Opioids during anesthesia in liver and renal failure].

Authors:  C Höhne; B Donaubauer; U Kaisers
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.